Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,396.62 134.06 0.82%
S&P 500 1,858.31 15.33 0.83%
NASDAQ 4,075.96 41.80 1.04%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Bayer Announces 2013 Recipients of Bayer Hemophilia Awards Program



      Bayer Announces 2013 Recipients of Bayer Hemophilia Awards Program

Multiple U.S. Researchers among Recipients to Receive Prestigious Award

PR Newswire

WAYNE, N.J., July 9, 2013

WAYNE, N.J., July 9, 2013 /PRNewswire/ -- Bayer HealthCare has announced the
2013 recipients of the Bayer Hemophilia Awards Program (BHAP). This year, the
company awarded more than $2 million in funding to 16 recipients in nine
countries, including six in the U.S. BHAP is the largest program of its kind
in hemophilia, funding innovative research and educational initiatives around
the world.

Since its founding in 2002, BHAP has awarded more than 220 grants, totaling
more than $26 million, to researchers and caregivers from 30 countries around
the world. BHAP support has contributed to more than 400 publications, poster
presentations and other scientific communications by awardees.

"We're thrilled to honor this year's award recipients, whose research will
help provide greater understanding of many aspects of hemophilia in the
future," said Prasad Mathew, Vice President, Global Medical Affairs
Hematology, Bayer HealthCare. "BHAP is a reflection of Bayer's ongoing
commitment to research that advances scientific understanding of hemophilia,
and helps improve patient care." 

Research funding will cover many different aspects of hemophilia such as
overcoming immunological barriers to AAV gene therapy, and stem cell
transplantation therapy for hemophilia, among others. This year's U.S. winners
include:

  o Carl Blobel, Weill Medical College of Cornell University
  o Cathy Buranahirun, Children's Hospital Los Angeles
  o Paris Margaritis, The Children's Hospital of Philadelphia
  o David Markusic, the University of Florida
  o Quang Duc Tran, Emory University
  o Grace Monis, University of Washington Medical Center

"I'm honored to be named a 2013 BHAP award recipient, and I'm excited to
continue my research on how Latino adolescents with hemophilia learn and use
medical information," said Dr. Cathy Buranahirun of Children's Hospital Los
Angeles. "Thanks to Bayer's generous support, I'm hopeful that this research
will provide the medical community with a better understanding of how to
approach and work with Spanish-speaking patients and families to improve their
overall care as they transition to the adult care setting."

Dr. Paris Margaritis was awarded an Early Career Investigator Award in 2011 to
study the role of the endothelial protein C receptor (EPCR) in the mechanism
of action of FVIIa in hemophilia treatment. Through his research, Dr.
Margaritis found that this receptor can enhance the function of FVIIa
following its administration in response to injury in vivo in mice. The
findings have been presented at several international symposia, including ISTH
2013, and formed the basis for the Bayer Special Project grant that he was
awarded this year. In that study, Dr. Margaritis aims to shed more light on
how EPCR effects such enhancement on the hemostatic function of FVIIa
administration.

The 2013 BHAP award recipients were announced at the XXIV Congress of the
International Society on Thrombosis and Haemostasis (ISTH). BHAP awardees are
selected by a global panel of distinguished hemophilia clinicians, researchers
and caregivers.

This year, awards were presented in the following categories: Special Projects
– which provides support for a wide range of scientific research; Early Career
Investigator – which provides salary support and research funds for junior
faculty members to undertake mentored and/or basic research projects;
Fellowship Project – which facilitates the development of specific clinical
expertise for applicants who have completed medical training; and Caregiver –
which recognizes the essential role of caregivers and allied health
professionals.

To learn more about BHAP and other 2013 award winners, please visit
http://www.bayer-hemophilia-awards.com/about_the_program/?view=past_awards. 

About the Bayer Hemophilia Awards Program
The Bayer Hemophilia Awards Program (BHAP) supports basic and clinical
research and education in hemophilia. Through grants provided to early career
investigators, fellows in training and other hemophilia care professionals,
the program seeks to support the next generation of care and treatment options
for people with hemophilia worldwide. For more information about BHAP, please
visit www.bayer-hemophilia-awards.com.

About Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals
business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare
is one of the world's leading, innovative companies in the healthcare and
medical products industry, and combines the activities of the Animal Health,
Consumer Care, Medical Care, and Pharmaceuticals divisions. As a specialty
pharmaceutical company, Bayer HealthCare provides products for Neurology,
Oncology, Cardiopulmonary and Women's Healthcare. The company's aim is to
discover and manufacture products that will improve human health worldwide by
diagnosing, preventing and treating diseases.

BAYER and the Bayer Cross are registered trademarks of Bayer.

Intended for U.S. Media Only

Forward-looking Statements

This news release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. These
factors include those discussed in Bayer's public reports which are available
on the Bayer website at www.bayer.com. The company assumes no liability
whatsoever to update these forward-looking statements or to conform them to
future events or developments.

SOURCE Bayer HealthCare

Website: http://www.berlex.com
Contact: Jane Ward, Bayer HealthCare, +1-973-420-2876, Jane.ward@bayer.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement